Breast cancer survivors' intentions of managing lymphedema

被引:42
作者
Fu, MR [1 ]
机构
[1] NYU, Coll Nursing, New York, NY 10003 USA
关键词
breast cancer; experience; lymphedema; management; phenomenology; survivors;
D O I
10.1097/00002820-200511000-00007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to describe the experience of managing lymphedema in breast cancer survivors. A descriptive phenomenological method was used as a guide for developing a bracket, gathering data, and analyzing data. A cross-sectional design with a purposive sampling technique was employed. During the 3 private, semi-structured, audio-recorded interviews with each woman, 12 breast cancer survivors described how they managed lymphedema in their daily lives. A taxonomy of 3 levels was created to describe the essential structures of the experience from general, to mediating, to specific: revelatory intention, cluster intention, and unit intention. The study revealed that the women's major intentions of managing lymphedema were to keep in mind the consequences, prevent lymphedema from getting worse, get ready to live with lymphedema, and integrate the care of lymphedema into daily life. Findings of the study provided an insightful alternative to the compliance approach to lymphedema management. Instead of merely evaluating breast cancer survivors' degree of compliance with treatment, it is suggested that researchers and practitioners should also assess the impact of the presence or absence of the women's intentions on lymphedema management.
引用
收藏
页码:446 / 457
页数:12
相关论文
共 58 条
[1]  
Albaugh Jeffrey A, 2003, Oncol Nurs Forum, V30, P593, DOI 10.1188/03.ONF.593-598
[2]  
[Anonymous], INNOVATIONS BREAST C
[3]  
Armer J, 2005, CANCER NURS, V28, P200
[4]  
Armer JM, 2004, LYMPHOLOGY, V37, P73
[5]  
Baron Roberta H, 2002, Oncol Nurs Forum, V29, P651, DOI 10.1188/02.ONF.651-659
[6]  
Boris M, 1997, Oncology (Williston Park), V11, P99
[7]  
Brennan MJ, 1998, CANCER, V83, P2821, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2821::AID-CNCR33>3.0.CO
[8]  
2-G
[9]  
Carter B J, 1997, Oncol Nurs Forum, V24, P875
[10]  
Davis S, 1998, Radiol Technol, V70, P42